Pharmacometric Analysis of the Relationship Between Absolute Lymphocyte Count and Expanded Disability Status Scale and Relapse Rate, Efficacy End Points, in Multiple Sclerosis Trials-Reference-Cited by-同舟云学术

Pharmacometric Analysis of the Relationship Between Absolute Lymphocyte Count and Expanded Disability Status Scale and Relapse Rate, Efficacy End Points, in Multiple Sclerosis Trials

Published:2018-05-10 Issue:10 Volume:58 Page:1284-1294
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Novakovic A.M.¹²,Thorsted A.¹,Schindler E.¹,Jönsson S.¹,Munafo A.³,Karlsson M.O.¹

Affiliation:

1. Department of Pharmaceutical Biosciences; Uppsala University; Uppsala Sweden

2. Current affiliation: Pharmacometry; Merck KGaA; Darmstadt Germany

3. Merck Institute for Pharmacometrics, Lausanne, Switzerland (part of Merck Serono S.A. Coinsins, Switzerland; an affiliate of Merck KGaA; Darmstadt Germany)

Funder

Innovative Medicines Initiative

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.1136/fullpdf

Reference37 articles.

1. The spectrum of multiple sclerosis;Heard;Curr Allergy Asthma Rep.,2007

2. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS);Kurtzke;Neurology.,1983

3. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course;Weinshenker;Brain.,1989